Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
ClinicalTrials.gov ID
NCT01114581
Lead Sponsor
Reckitt Benckiser LLCINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
38Actual
Last Update Posted
Sep 19, 2018Actual
Start Date
Apr 2010
Primary Completion Date
Apr 2011Actual
Completion Date
Apr 2011Actual
Brief Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
Acute Respiratory Infection
Mucinex
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Symptoms of cough, thickened mucus and chest congestion
Able to produce sputum
Non Smoker
Exclusion Criteria:
Pregnant
Smokers
Fever above 101°F
Any chronic illness
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Triple
No central contacts
There are no central contacts for this study.
Center for Environmental Medicine, Asthma, and Lung Biology